Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Publication year range
1.
Int J Immunopathol Pharmacol ; 24(3): 683-93, 2011.
Article in English | MEDLINE | ID: mdl-21978700

ABSTRACT

Solid tumors such as head and neck squamous cell carcinoma (HNSCC) display an intense interaction between tumoral factors and the immune system. Functional modulation of tumor-infiltrating and peripheral blood immune cells plays an important role during tumor progression. In this pilot study we compared biological functions of polymorphonuclear granulocytes (PMN) from the peripheral blood of HNSCC patients and healthy subjects. PMN were simultaneously isolated from the peripheral blood of HNSCC patients and healthy donors for functional analysis (apoptosis, production of reactive oxygen species (ROS), cytokine release and immunophenotyping). PMN from HNSCC patients showed a significantly lower inducible production of ROS (P = 0.02) and reduced spontaneous apoptosis (P= 0.008) compared with PMN from healthy donors. Under standard culture conditions, there was no significant difference regarding the release of inflammatory cytokines between PMN from HNSCC patients and PMN from healthy donors. Confirming previous observations, serum concentrations of PMN-related cytokines were significantly higher in the peripheral blood of HNSCC patients than in that of controls. Importantly, immunophenotyping revealed an increased number of immature PMN in PMN fractions isolated from HNSCC patients. Peripheral blood PMN from HNSCC patients and healthy donors show distinct functional differences. The presence of increased numbers of immature stages of PMN in HNSCC patients may partly contribute to the changes observed. After recruitment to and infiltration of the tumor, PMN may be further modulated in the local tumor microenvironment. This pilot study justifies functional analyses of myeloid cells in larger cohorts of patients with HNSCC.


Subject(s)
Carcinoma, Squamous Cell/pathology , Granulocytes/pathology , Head and Neck Neoplasms/pathology , Neutrophils/pathology , Aged , Aged, 80 and over , Apoptosis/physiology , Carcinoma, Squamous Cell/metabolism , Cell Line, Tumor , Chemokine CCL4/metabolism , Cytokines/blood , Enzyme-Linked Immunosorbent Assay , Female , Flow Cytometry , Granulocytes/metabolism , Head and Neck Neoplasms/metabolism , Humans , Interleukin-8/metabolism , Macrophage Migration-Inhibitory Factors/metabolism , Male , Middle Aged , Neutrophils/metabolism , Pilot Projects , Respiratory Burst/physiology
2.
Laryngorhinootologie ; 90(3): 168-77, 2011 Mar.
Article in German | MEDLINE | ID: mdl-21380962

ABSTRACT

Despite multiple medical and scientific achievements, cancer remains a leading cause of death worldwide. Next to imaging technologies, molecular methods for early detection and for monitoring of the course of disease are of increasing interest. Thus, over the past years numerous studies have focused on the identification of biomarkers for cancer diagnosis, prognosis and response to therapy. The study of biomarkers seems to pose a high degree of complexity because many different types of molecules may, in principle, serve as potential biomarkers. In addition, these molecules can be produced either by the tumor or by the tumor-host in response to the presence of cancer. In this review the authors will address several major topics encompassed by the field of biomarker research. They will discuss the primary sources from which biomarker candidates can be 'mined' as well as the technological or methodological challenges associated with identification of biomarkers. Furthermore, the review will focus on current biomarker candidates for head and neck squamous cell carcinoma (HNSCC), with particular interest on several molecules yielding potential relevance for detection and prognosis of this type of cancer. Finally, several biomarker candidates with predictive potential for the response to therapy of HNSCC patients will be discussed, since identifying such molecules is crucial for developing individually-tailored and improved therapeutic strategies.


Subject(s)
Biomarkers, Tumor/analysis , Carcinoma, Squamous Cell/diagnosis , Otorhinolaryngologic Neoplasms/diagnosis , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/therapy , Chromosome Aberrations , Early Diagnosis , Human papillomavirus 16 , Humans , Immunoenzyme Techniques , Otorhinolaryngologic Neoplasms/genetics , Otorhinolaryngologic Neoplasms/pathology , Otorhinolaryngologic Neoplasms/therapy , Papillomavirus Infections/diagnosis , Papillomavirus Infections/genetics , Papillomavirus Infections/pathology , Papillomavirus Infections/therapy , Prognosis , Proteomics , Reverse Transcriptase Polymerase Chain Reaction , Treatment Outcome
3.
Cell Mol Life Sci ; 64(2): 181-91, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17131060

ABSTRACT

Rhinoviruses, which cause common cold, belong to the Picornaviridae family, small non-enveloped viruses (diameter 15-30 nm) containing a single-stranded RNA genome (about 7 kb). Over 100 different rhinoviral serotypes have been identified thus far, establishing rhinoviruses as the most diverse group of Picornaviridae. Based on receptor binding properties, rhinoviruses are divided into two classes: the major group binding to intracellular adhesion molecule-1 and the minor group binding to the very low density lipoprotein receptors. Interactions between virus and the receptor molecules cause a conformational change in the capsid, which is a prerequisite for viral uptake. Rhinoviruses trigger a chemokine response upon infection that may lead to exacerbation of the symptoms of common cold, i.e. asthma and inflammation. The following review aims to summarize the knowledge about rhinoviral infections and discusses therapeutical approaches against this almost perfectly adapted pathogen.


Subject(s)
Capsid Proteins/genetics , Capsid/chemistry , Common Cold/drug therapy , Common Cold/virology , Rhinovirus/metabolism , Signal Transduction/genetics , Antiviral Agents/therapeutic use , Capsid/ultrastructure , Common Cold/immunology , Cytokines/immunology , Humans , Intercellular Adhesion Molecule-1/metabolism , Receptors, LDL/metabolism , Receptors, Virus/metabolism , Rhinovirus/classification
4.
Oncogene ; 25(41): 5612-25, 2006 Sep 14.
Article in English | MEDLINE | ID: mdl-16636669

ABSTRACT

We have previously shown that activation of the acid sphingomyelinase (ASM), the release of ceramide and the formation of ceramide-enriched membrane domains are central for the induction of apoptosis by CD95. Here, we demonstrate that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and CD95 activate the ASM via a redox mechanism resulting in release of ceramide and formation of ceramide-enriched membrane platforms. Ceramide-enriched membrane platforms serve to cluster DR5 upon stimulation. Antioxidants prevent TRAIL-mediated stimulation of ASM, the release of ceramide, the formation of ceramide-enriched membrane platforms and the induction of apoptosis by TRAIL. Further, ASM-deficient splenocytes fail to cluster DR5 in ceramide-enriched membrane domains upon TRAIL stimulation and resist TRAIL-induced apoptosis, events that were restored by addition of natural C(16)-ceramide. A dose-response analysis indicates that ceramide-enriched membrane platforms greatly sensitized tumor cells to TRAIL-induced apoptosis. Our data indicate that ceramide-enriched membrane platforms are required for the signaling of TRAIL-DR5 complexes under physiological conditions.


Subject(s)
Apoptosis Regulatory Proteins/physiology , Apoptosis/physiology , Ceramides/metabolism , Membrane Glycoproteins/physiology , Sphingomyelin Phosphodiesterase/metabolism , Tumor Necrosis Factor-alpha/physiology , Animals , Cell Line , Enzyme Activation , Humans , Immunohistochemistry , Mice , Oxidation-Reduction , TNF-Related Apoptosis-Inducing Ligand
SELECTION OF CITATIONS
SEARCH DETAIL
...